Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

about

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

Item

http://www.wikidata.org/entity/Q47871150

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@en

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@nl

type

Item

label

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@en

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@nl

prefLabel

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@en

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@nl

P1476

Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls.

@en

P2093

Birger Thorsteinsson

http://www.w3.org/2001/XMLSchema#string

Ulrik Pedersen-Bjergaard

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Reduced awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms.

Hypoglycemia Event Rates: A Comparison Between Real-World Data and Randomized Controlled Trial Populations in Insulin-Treated Diabetes.

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Self-reported non-severe hypoglycaemic events in Europe.

Treat-to-target trials: uses, interpretation and review of concepts.

Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.

Substantial reductions in the number of diabetic ketoacidosis and severe hypoglycaemia episodes requiring emergency treatment lead to reduced costs after structured education in adults with Type 1 diabetes.

Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical

P2888

s11892-017-0965-1

P304

131

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11892-017-0965-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29080929

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

hypoglycemia